Breast cancer patients testified that Roche Holding AG's (ROG.VX) Avastin saved their lives as U.S. health officials weighed whether the world's best-selling cancer drug should remain approved for that condition. At stake in the hearing that began Tuesday is nearly $1 billion in annual Avastin revenues, the hopes of cancer patients and the resolve of the Food and Drug Administration to stick to data-based decisions. "I am alive due to Avastin," said 66-year-old Patricia Howard. "I'm a wife, mother, sister, aunt and granny. I'm not just a statistic. It's in your hands to make sure I don't become one."
